Gustav Vik (to the left) from Kjellervolla school and Martin Dimov from Mailand school are collaborating in the laboratory to isolate T cells. Photo: Bente Prestegård.

Research talents learned about immunotherapy

Gustav Vik from Killevold school and Martin Dimov from Mailand school are enjoying the gatherings arranged by Talentsenteret for realfag: “This is very interesting because we are learning things that are not part of the curriculum and we like to learn about current topics.”

This article was first published in Norwegian on our School Collaboration website.

A group of talented science students from Oslo and Akershus spent two days learning about immunotherapy from former cancer researchers, who are now teachers at Ullern Upper Secondary School and researchers at Thermo Fisher Scientific.

Collaboration partners: Oslo Cancer Cluster, Thermo Fisher Scientific Norway, Ullern Upper Secondary School, Norsk teknisk museum (The Norwegian Museum of Science and Technology) and Oslo Vitensenters Talentsenter i realfag (Talent centre for the natural sciences)

In February, 25 students from 19 different schools in Oslo, which are a part of “Talentsenteret for realfag” (Talent Centre for the Natural Sciences), arrived together to Oslo Cancer Cluster Innovation Park and Ullern Upper Secondary School.

The students were there to participate in a specially tailored two-day programme about medical research and the use of immunotherapy to treat cancer.

The days were spent partly in a classroom to learn about the theory of the immune system and partly in a laboratory to learn how to isolate a type of cells in the immune system called T cells. The method the students learned about is used in modern cell therapies against cancer, which are called CAR T therapies.

Gustav Vik from Kjellervolla School and Martin Dimov from Mailand School are enjoying the gatherings arranged by Talentsenteret for realfag: “This is very interesting because we are learning things that are not part of the ordinary school syllabus and we like to learn about current topics.”

Kaja Flote from Hellerasten school is looking in the microscope to find T cells. She thinks it is exciting to learn more about the depth of the immune system and how it can be changed to fight cancer. Photo: Bente Prestegård.

Kaja Flote from Hellerasten School is looking in the microscope to find T cells. She thinks it is exciting to learn more about the complexity of the immune system and how it can be changed to combat cancer. Photo: Bente Prestegård.

The next day, the students visited the production facilities of Thermo Fisher Scientific Norway, located in Lillestrøm. This is where the company makes Dynabeads (also known as “Ugelstadkulene” in Norwegian) to be used in five billion diagnostic tests every year and in CAR T therapies against cancer.

The Norwegian TV channel TV2 has produced this news segment about Emily Whitehead (link in Norwegian), the first child in the world who received CAR T therapy to treat her cancer, which was deemed incurable. The segment was recorded in 2019, when Emily and her family visited the Norwegian employees at Thermo Fisher Scientific in Oslo. Emily is today 13 years old and has been cancer-free for over eight years.

You can read more about the students’ experience at Thermo Fisher Scientific in this article from 2017, when another group of students from Ullern Upper Secondary School visited the same production facilities.

The researcher Morten Fure from Thermo Fisher tells the students about Dynabeads, also known as “Ugelstadkulene”, CAR T therapy, immunotherapy, and cancer. He has prepared T cell solutions that the students will look at in the microscope. Photo: Bente Prestegård.

The researcher Morten Luhr from Thermo Fisher Scientific tells the students about Dynabeads (also known as “Ugelstadkulene”), CAR T therapy, immunotherapy, and cancer. He has prepared T cell solutions that the students will look at in the microscope. Photo: Bente Prestegård.

The background to the collaboration

“Talentsenteret i realfag” (link in Norwegian) is a customised educational option for students who are especially strong academically. It is for those students who find that the standard school curriculum does not challenge them enough. Just like the school adapts the teaching for students who need extra help in subjects, they adapt the teaching for students who already know a lot and want to learn even more. This is a group of students with a high degree of motivation and a hunger for knowledge that is extraordinary.

The centre employs experts in different subjects to give the students the academic challenges they need. That is why this two-day programme in medicine and immunotherapy was held in February.

The programme was developed by employees from Thermo Fisher Scientific and two teachers from Ullern Upper Secondary School. Fet and Flydal Jenstad both have backgrounds as cancer researchers at the Institute for Cancer Research and the Institute of Cancer Genetics and Informatics respectively. Fet and Flydal Jenstad share the responsibility for the new researcher programme at Ullern Upper Secondary School. Read more about the researcher programme here (link in Norwegian).

Oslo Cancer Cluster and Ullern Upper Secondary School have a school collaboration project since 2009. The goal is to contribute to educating the researchers and entrepreneurs of the future.

Thermo Fisher Scientific is a global biotech company with strong Norwegian roots through the acquisition of the Norwegian biotech Dynal. Thermo Fisher Scientific is one of the members of Oslo Cancer Cluster and actively participates in the school collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School.

Read articles about the other school collaborations Thermo Fisher Scientific have participated in:

 

Click here to sign up for Oslo Cancer Cluster Newsletter

Moina Medbøe Tamuly (to the left) and his colleage Sondre Tagestad from NTENTION test the drone glove on Devon Island. Photo: Haughton-Mars Project

From Ullern to Mars

Moina Medbøe Tamuly (to the left) and his colleage Sondre Tagestad from NTENTION test the drone glove on Devon Island.

Read this article in Norwegian on our School Collaboration website.

A former Ullern student with an unusual career came to inspire current students in December.

Moina Medbøe Tamuly was in his final year at Ullern Upper Secondary School in 2014. Before Christmas in 2019, he came back to Ullern to tell today’s students about his exciting life after graduation.

Since Moina Medbøe Tamuly exited the school gates of Ullern Upper Secondary School for the very last time in June 2014, he has managed to spend two years in military service, worked in Trondheim, Oslo, Beijing, Shanghai, Amsterdam, Las Vegas, Brazil and the Arctic.

Moreover, he has an adventurous personality, combined with a passion for technology, which made him start the company NTENTION with his friend Magnus Arveng.

Magnus had the idea of a glove that could control drones, which he and Moina, together with their skilled team, has brought to life. The ground-breaking gloves can simplify the steering of everything from drones to VR interaction, music and robot arms. Their vision has been to develop a technology that is a natural and seamless extension of the human, instead of being an external instrument.

This has aroused the interest of the founder of the Mars Institute, Dr. Pascal Lee, who is collaborating with NASA on missions to the Moon and the exploration of Mars. The adventurous journey brought Moina all the way to Devon Island, a Mars-like, uninhabited island in the Arctic, together with his colleague Sondre Tagestad in NTENTION. During their stay, they tested if the glove could be used as an interactive instrument in conceptual space suits.

NTENTION’s collaboration partners at the Mars Institute/SETI Institute say in the article above that the glove “is revolutionary for future human exploration of the moon and Mars – and potential other planets”.

Right before Christmas 2019, Moina went back to his old upper secondary school, Ullern, to tell the students there today what life after graduation can be like.

Not a straightforward task

Moina tells the students the journey to Devon Island and the collaboration with astronauts has not been simple and straightforward, but has included many ups, downs and detours.

The students have brought their lunches into Kaare Norum auditorium to hear what the former Ullern student has to say about life after graduation.

Moina Medbøe Tamuly is back on his old hunting grounds, telling Ullern students about life after graduation.

Moina Medbøe Tamuly is back on his old hunting grounds, telling Ullern students about life after graduation. Photo: Elisabeth Kirkeng Andersen

At Ullern, Moina studied physics, history, philosophy and chemistry.

“I wasn’t very good at physics. I thought it was a really demanding subject, but also very exciting,” Moina says.

“After I graduated, I was really sick and tired of school. Then I had to do military service, something I wasn’t exactly thrilled about in the beginning. I was immature and created some disorder, but eventually I started liking it so much that I stayed there for two years. I was even accepted to The Royal Norwegian Naval Academy, which would have been an adventurous opportunity that I still daydream about sometimes.”

After the military service, Moina studied Industrial Economy and Technology Leadership at NTNU. In the passionate and teeming student atmosphere at NTNU, Moina met his business partner and friend Magnus Arveng and their company NTENTION was born.

Moina says that when he was a student at Ullern, he liked the subjects, the other students, the teachers and working for the student council. The first period at NTNU was a shock after such an enjoyable period of upper secondary school and military service.

“When I moved to Trondheim to study at NTNU, everything became chaotic. I had a breakdown and became depressed. It was a big transition from the military service, where I had great co-workers and a lot of responsibility, to academic studies. Our company saved me. It was pure magic to come back to an environment where you cooperate closely with one another to reach results together – and to be able to see the results of what you do every day,” Moina says.

Moina believes this is a reality many students can recognise and that it is important to learn that things don’t always go the way you planned, no matter how hard you work.

The company the students started together now has 13 employees in different roles and functions.

Doctor Pascal Lee, Head of the Research Station on Devon Island and space researcher at the Mars Institute is trying out the glove from NTENTION. Photo: Haughton-Mars Project

Dr. Pascal Lee, Head of the Research Station on Devon Island and space researcher at the Mars Institute, is trying out the glove from NTENTION. Photo: Haughton-Mars Project

The journey is as important as the goal

“I am not here to talk about what I have achieved, but about my life and the journey to get here,” Moina says to the Ullern students.

After showing the drone glove to interested students by using presentation slides and a video, Moina asks if there are any questions from the audience. Many hands go up in the air and they wonder how on Earth NTENTION got in touch with researchers that collaborate with NASA.

“It was very random. We met Dr. Pascal Lee at a conference arranged by Energy Valley. We knew the organisers and they gave us a stand for free. The glove we had developed can be used for music and art too. DJs can use it to play their set and combine it with video. So, together with the artist duo Broslo, we had arranged a unique stand with exciting artwork and video clips. That is where we started talking with Lee.”

A friendship developed between Lee, Moina and the others in NTENTION. Moina wants to highlight that you often meet friendly professionals if you dare to get in touch with them, one of the most important lessons from his journey so far.

“Our solution was a good fit with his visions and the need to explore Mars, so we began to work together,” Moina says.

The Ullern students’ lunch break is almost over, so Moina begins to sum up.

Devon Island is where NTENTION and Moina have tested the drone glove for the Mars Institute. Photo: Moina Medbøe Tamuly.

Devon Island is where NTENTION and Moina have tested the drone glove for the Mars Institute. Photo: Moina Medbøe Tamuly.

Time will be the judge of whether the drone glove Moina has developed one day will be a part of the space suits and equipment astronauts will use when landing on the Moon and Mars.

“The world will be more complicated and difficult when you graduate from Ullern, but all the more exciting. The last years of my life have been a little chaotic. It has been about closing deals and travelling around the world to find opportunities without a regular schedule. I finally learned that all people need to have a little bit of structure and to be part of a whole to thrive. In the end, I have unique experiences. My intellect has been nourished, I feel truly inspired and I am humbled to be a part of the journey where we are working to spearhead technological developments,” says Moina.

Sign up to our monthly newsletter

Cancer Crosslinks 2020 gathered a distinguished group of national and international speakers, and received a record number of meeting delegates.

Cancer Crosslinks 2020

The speakers, chairpersons, introducers and organizers of Cancer Crosslinks 2020Oslo Cancer Cluster

Engaging presentations by leading international and Norwegian oncology experts at the 12th Cancer Crosslinks “Progress in Cancer Care – A tsunami of promises or Game Changing Strategies?”.

Oslo Cancer Cluster’s annual meeting gathered more than 350 delegates from all over Norway at the Oslo Cancer Cluster Innovation Park, and more than 50 participants followed the live stream. The record high participation shows the large interest in translational cancer research and the importance of the programme for the Norwegian oncology community.

Cancer Crosslinks has become one of the largest national meeting places for oncologists, haematologists, translational researchers, regulatory experts and industry representatives. The meeting offers a full day educational program.

The aim of the conference is to stimulate broader interactions between researchers and clinicians, to encourage translational and clinical research, and to inspire collaborations. Novel partnerships between industry, academia and authorities are essential to deliver new treatments and diagnostics to Norwegian cancer patients.

“At the start of 2020, cancer patients have more treatment options than ever before. Immuno-oncology is firmly established as the fourth pillar of cancer treatment and the tremendous progress in the field is reflected in increased survival rates,” said Jutta Heix, Head of International Affairs, Oslo Cancer Cluster. “However, many patients do not benefit from novel treatments and we still have significant gaps in our understanding of the complex biological mechanisms. Deciphering this complexity is a task for the decade to come. The Cancer Crosslinks 2020 speakers are shedding light on emerging concepts and key challenges and discuss how they are addressing them to advance cancer care.”

The audience at Cancer Crosslinks 2020.

The audience at Cancer Crosslinks 2020. Photo: Cameo Productions UB/Oslo Cancer Cluster

An inspiring programme

Referring to a record number of new oncology drug approvals in recent years and an enormous global pipeline of drugs in late-stage development, this year’s programme addressed the question “Progress in Cancer Care – A Tsunami of Promises or Game-Changing Strategies?”. Distinguished international experts from leading centres in the US and Europe presented emerging concepts, recent progress and key questions to be addressed for both solid and haematological cancers.

Cancer researchers and clinicians from all of Norway enjoyed excellent presentations and engaging discussions with speakers and colleagues.

“Cancer Crosslinks 2020 gave me an opportunity to listen to talks by international top scientists, and discuss some of the latest developments in translational cancer research with meeting participants from academia and industry in a relaxed and inspiring setting,” said Johanna Olweus, Head of Department of Cancer Immunology at the Institute for Cancer Research.

“Cancer Crosslinks is always a meeting that makes me proud of being part of Oslo Cancer Cluster. It is inspiring to see Norwegian and international participants come together to discuss recent progress in cancer research and how to develop cancer treatments for the patients,” said Øyvind Kongstun Arnesen, Chairman of the Board, Oslo Cancer Cluster.

The day programme was complemented with an evening reception in the city center where speakers and delegates continued their lively discussions and listened to an inspiring talk by Ole Petter Ottersen, President of Karolinska Institute, at Hotel Continental in Oslo.

Cancer Crosslinks was established by Oslo Cancer Cluster in 2009 in collaboration with the pharmaceutical company Bristol-Myers Squibb.

“Cancer Crosslinks 2020 has been a fantastic conference, where the presenters have given an excellent description of current and near future achievements within cancer research and the importance of understanding the underlying biology of cancer to rationally give patients the correct cancer therapy. In particular within immunotherapy, there is a need to understand the dynamic complexity of tumor immunology and how to apply the best and tailored immuno-oncology based treatment strategy for cancer patients,” said Ali Areffard, Disease Area Specialist Immuno-Oncology, Bristol-Myers Squibb.

This year, the pharmaceutical company Sanofi Genzyme Norway was a proud co-sponsor of the meeting.

“It was great to be able to provide a platform for interaction between the Norwegian scientific cancer environment and top international research capacities. Therefore, it was with huge enthusiasm Sanofi Genzyme co-sponsored this important conference. New treatment options in oncology are developing fast, where new treatment modalities provide clinicians with additional and superior options. New treatments specifically targeting the malignant cells, as well as activating the host immune response towards the cancer, provides tools to significantly improve current cancer treatments. This year’s Cancer Crosslinks conference gave an excellent insight into this,” said Knut Steffensen, Medical Advisor Hematology Nordic & Baltics, Sanofi Genzyme.

Interview with Prof. Jason Luke

View the interview with Prof. Jason Luke, by HealthTalk, in the video below:

Interview with Prof. Michel Sadelain

View the interview with Prof. Michel Sadelain, by HealthTalk, in the video below:

The speakers at Cancer Crosslinks 2020

Jason J. Luke, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, University of Pittsburgh Medical Center and Hillman Cancer Center

Jason J. Luke, MD, FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, University of Pittsburgh Medical Center and Hillman Cancer Center, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster

Stefani Spranger, Howard S. and Linda B. Stern Career Development Assistant Professor, Koch Institute for Integrative Cancer Research at MIT, Cambridge

Stefani Spranger, Howard S. and Linda B. Stern Career Development Assistant Professor, Koch Institute for Integrative Cancer Research at MIT, Cambridge, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster

Harriet Wikman, Professor, Group Leader, Center for Experimental Medicine, Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf

Harriet Wikman, Professor, Group Leader, Center for Experimental Medicine, Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster

Vessela Kristensen, Professor, Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital

Vessela Kristensen, Head of Research and Development and Director of Research at the Dept. of Medical Genetics, Oslo University Hospital, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster

Peter A. Fasching, Professor of Translational Gynecology and Obstetrics, University Hospital and Comprehensive Cancer Center Erlangen-EMN

Peter A. Fasching, Professor of Translational Gynecology and Obstetrics, University Hospital and Comprehensive Cancer Center Erlangen-EMN, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster

Karl Johan Malmberg, Professor, Group Leader Dept. of Cancer Immunology and Director STRAT-CELL, Oslo University Hospital, Norway.

Karl Johan Malmberg, Professor, Group Leader Dept. of Cancer Immunology and Director STRAT-CELL, Oslo University Hospital, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster

Michel Sadelain, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center

Michel Sadelain, MD, PhD, Professor, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster

Bjørn Tore Gjertsen, Consultant Hematology, Haukeland University Hospital, Norway.

Bjørn Tore Gjertsen, Professor of Hematology, Centre for Cancer Biomarkers CCBIO, Dept. of Clinical Science, University of Bergen, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster

Hermann Einsele, Professor, Chair, Dept. of Internal Medicine II, Head of the Clinical and Translational Research Program on Multiple Myeloma, Wuerzburg University Hospital

Hermann Einsele, Professor, Chair, Dept. of Internal Medicine II, Head of the Clinical and Translational Research Program on Multiple Myeloma, University Hospital Wuerzburg, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster

 

Sign up to our monthly newsletter

Cancer Crosslinks panel discussion 2019. Photo: Fullscreen Visuals/Oslo Cancer Cluster

Welcome to Cancer Crosslinks 2020

Discussing health care at Cancer Crosslinks 2019

This year’s Cancer Crosslinks has received a record number of bookings. If you are not able to attend the conference, a live stream will be available below or via this link during the entire event.

 

Your browser does not support frames which is required to watch the webcast. Try accessing it here instead.